全文获取类型
收费全文 | 1095490篇 |
免费 | 78273篇 |
国内免费 | 1995篇 |
专业分类
耳鼻咽喉 | 15145篇 |
儿科学 | 28892篇 |
妇产科学 | 26435篇 |
基础医学 | 154270篇 |
口腔科学 | 31646篇 |
临床医学 | 96886篇 |
内科学 | 218404篇 |
皮肤病学 | 21860篇 |
神经病学 | 88814篇 |
特种医学 | 42522篇 |
外国民族医学 | 92篇 |
外科学 | 176238篇 |
综合类 | 20202篇 |
现状与发展 | 4篇 |
一般理论 | 431篇 |
预防医学 | 74190篇 |
眼科学 | 25792篇 |
药学 | 83163篇 |
3篇 | |
中国医学 | 2348篇 |
肿瘤学 | 68421篇 |
出版年
2021年 | 8196篇 |
2019年 | 8532篇 |
2018年 | 12032篇 |
2017年 | 9256篇 |
2016年 | 10370篇 |
2015年 | 12008篇 |
2014年 | 16595篇 |
2013年 | 24771篇 |
2012年 | 34467篇 |
2011年 | 36236篇 |
2010年 | 21125篇 |
2009年 | 20085篇 |
2008年 | 35152篇 |
2007年 | 37023篇 |
2006年 | 37400篇 |
2005年 | 36635篇 |
2004年 | 35255篇 |
2003年 | 33823篇 |
2002年 | 32991篇 |
2001年 | 56102篇 |
2000年 | 57590篇 |
1999年 | 48425篇 |
1998年 | 12900篇 |
1997年 | 11335篇 |
1996年 | 11192篇 |
1995年 | 10392篇 |
1994年 | 9584篇 |
1993年 | 8850篇 |
1992年 | 36469篇 |
1991年 | 34797篇 |
1990年 | 33519篇 |
1989年 | 32635篇 |
1988年 | 29772篇 |
1987年 | 28924篇 |
1986年 | 27075篇 |
1985年 | 26008篇 |
1984年 | 18987篇 |
1983年 | 16256篇 |
1982年 | 9353篇 |
1981年 | 8184篇 |
1979年 | 16530篇 |
1978年 | 11451篇 |
1977年 | 9811篇 |
1976年 | 8544篇 |
1975年 | 9163篇 |
1974年 | 11018篇 |
1973年 | 10308篇 |
1972年 | 9716篇 |
1971年 | 9113篇 |
1970年 | 8630篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
51.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
52.
53.
54.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
55.
56.
57.
58.
59.
Michael E Egger Joanna M Ohlendorf Charles R Scoggins Kelly M McMasters Robert C G Martin II 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2015,17(9):839-845
BackgroundThe aim of this paper is to assess the current state of quality and outcomes measures being reported for hepatic resections in the recent literature.MethodsMedline and PubMed databases were searched for English language articles published between 1 January 2002 and 30 April 2013. Two examiners reviewed each article and relevant citations for appropriateness of inclusion, which excluded papers of liver donor hepatic resections, repeat hepatectomies or meta-analyses. Data were extracted and summarized by two examiners for analysis.ResultsFifty-five studies were identified with suitable reporting to assess peri-operative mortality in hepatic resections. In only 35% (19/55) of the studies was the follow-up time explicitly stated, and in 47% (26/55) of studies peri-operative mortality was limited to in-hospital or 30 days. The time period in which complications were captured was not explicitly stated in 19 out of 28 studies. The remaining studies only captured complications within 30 days of the index operation (8/28). There was a paucity of quality literature addressing truly patient-centred outcomes.ConclusionQuality outcomes after a hepatic resection are inconsistently reported in the literature. Quality outcome studies for a hepatectomy should report mortality and morbidity at a minimum of 90 days after surgery. 相似文献
60.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献